<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>PMC</source>
  <date>20140719</date>
  <key>pmc.key</key>
  <document>
    <id>PMC4967940</id>
    <passage>
      <infon key="name_2">surname:Slawska;given-names:Jolanta</infon>
      <infon key="name_3">surname:Jacobs;given-names:Laura</infon>
      <infon key="name_0">surname:Engel;given-names:Katharina</infon>
      <infon key="name_1">surname:Rudelius;given-names:Martina</infon>
      <infon key="name_6">surname:Kurutz;given-names:Julia</infon>
      <infon key="alt-title">Katharina Engel et&#160;al</infon>
      <infon key="article-id_publisher-id">EMMM201506047</infon>
      <infon key="name_5">surname:Altmann;given-names:Bettina</infon>
      <infon key="name_8">surname:Fern&#225;ndez&#8208;S&#225;iz;given-names:Vanesa</infon>
      <infon key="name_9">surname:Brunner;given-names:Andr&#228;</infon>
      <infon key="lpage">862 862</infon>
      <infon key="fpage">851 851</infon>
      <infon key="year">2016</infon>
      <infon key="kwd">B&#8208;cell lymphoma mitosis ubiquitin USP9X XIAP Cancer Haematology</infon>
      <infon key="name_21">surname:Peschel;given-names:Christian</infon>
      <infon key="name_20">surname:Rosenwald;given-names:Andreas</infon>
      <infon key="name_22">surname:Bassermann;given-names:Florian</infon>
      <infon key="article-id_doi">10.15252/emmm.201506047</infon>
      <infon key="article-id_pmid">27317434</infon>
      <infon key="name_7">surname:Rathakrishnan;given-names:Abirami</infon>
      <infon key="source">EMBO Mol Med</infon>
      <infon key="issue">8</infon>
      <infon key="name_4">surname:Ahangarian Abhari;given-names:Behnaz</infon>
      <infon key="volume">8 8</infon>
      <infon key="article-id_pmc">4967940</infon>
      <infon key="license">This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</infon>
      <infon key="type">front</infon>
      <infon key="notes">

 () : &#8211;

</infon>
      <infon key="title">Subject Categories</infon>
      <infon key="name_18">surname:Keller;given-names:Ulrich</infon>
      <infon key="name_19">surname:Jost;given-names:Philipp J</infon>
      <infon key="name_10">surname:Targosz;given-names:Bianca&#8208;Sabrina</infon>
      <infon key="name_11">surname:Loewecke;given-names:Felicia</infon>
      <infon key="name_12">surname:Gloeckner;given-names:Christian Johannes</infon>
      <infon key="name_13">surname:Ueffing;given-names:Marius</infon>
      <infon key="name_14">surname:Fulda;given-names:Simone</infon>
      <infon key="name_15">surname:Pfreundschuh;given-names:Michael</infon>
      <infon key="name_16">surname:Tr&#252;mper;given-names:Lorenz</infon>
      <infon key="name_17">surname:Klapper;given-names:Wolfram</infon>
      <offset>0</offset>
      <text>USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B&#8208;cell lymphoma</text>
    </passage>
    <passage>
      <infon key="type">abstract_title_1</infon>
      <offset>105</offset>
      <text>Abstract</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>114</offset>
      <text>The mitotic spindle assembly checkpoint (SAC) maintains genome stability and marks an important target for antineoplastic therapies. However, it has remained unclear how cells execute cell fate decisions under conditions of SAC&#8208;induced mitotic arrest. Here, we identify USP9X as the mitotic deubiquitinase of the X&#8208;linked inhibitor of apoptosis protein (XIAP) and demonstrate that deubiquitylation and stabilization of XIAP by USP9X lead to increased resistance toward mitotic spindle poisons. We find that primary human aggressive B&#8208;cell lymphoma samples exhibit high USP9X expression that correlate with XIAP overexpression. We show that high USP9X/XIAP expression is associated with shorter event&#8208;free survival in patients treated with spindle poison&#8208;containing chemotherapy. Accordingly, aggressive B&#8208;cell lymphoma lines with USP9X and associated XIAP overexpression exhibit increased chemoresistance, reversed by specific inhibition of either USP9X or XIAP. Moreover, knockdown of USP9X or XIAP significantly delays lymphoma development and increases sensitivity to spindle poisons in a murine E&#956;&#8208;Myc lymphoma model. Together, we specify the USP9X&#8211;XIAP axis as a regulator of the mitotic cell fate decision and propose that USP9X and XIAP are potential prognostic biomarkers and therapeutic targets in aggressive B&#8208;cell lymphoma.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>1468</offset>
      <text>Introduction</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>1481</offset>
      <text>The spindle assembly checkpoint (SAC) is an important target in cancer therapy, and microtubule poisons such as taxanes and vinca alkaloids are widely used as highly effective chemotherapy agents (Manchado et&#160;al, 2012). The failure of tumor cells to initiate apoptosis during the active checkpoint signal is a major factor that limits the efficacy of antimitotic drugs (Janssen &amp; Medema, 2011). Therefore, the identification of factors that regulate mitotic survival is of imminent relevance, both in generating a mechanistic understanding of the SAC and for the identification of novel target structures in cancer therapy.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>2106</offset>
      <text>Pathways of the ubiquitin proteasome system are critically involved in SAC signaling, mediating both proteolysis&#8208;dependent and proteolysis&#8208;independent mechanisms (Lara&#8208;Gonzalez et&#160;al, 2012). Indeed, the target of the SAC is CDC20, which activates the anaphase&#8208;promoting complex/cyclosome (APC/C) that triggers anaphase and mitotic exit by ubiquitylating securin and cyclin B1 (Lara&#8208;Gonzalez et&#160;al, 2012). Other ubiquitin ligases, particularly members of the cullin ring ligase (CRL) family, regulate different aspects of mitotic spindle formation, mitotic survival, and chromosome alignment, respectively (Bassermann et&#160;al, 2014). By contrast, the role of deubiquitylases (DUBs) in mitotic control has remained more elusive.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>2844</offset>
      <text>Inhibitor of apoptosis proteins (IAP) are key negative regulators of cell death. Specific to the IAP member X&#8208;linked inhibitor of apoptosis protein (XIAP) is the ability to directly bind and inhibit activated caspases 3, 7, and 9 via its N&#8208;terminal baculoviral IAP repeat domains (BIR) (Deveraux et&#160;al, 1997; Chai et&#160;al, 2001; Riedl et&#160;al, 2001; Shiozaki et&#160;al, 2003). Notably, XIAP exerts ubiquitin ligase activity and promotes ubiquitylation of substrates such as RIPK2, but also regulates its own abundance via autoubiquitylation, an important mechanism for maintaining XIAP homeostasis (Vaux &amp; Silke, 2005) (Damgaard et&#160;al, 2012). Increased expression of XIAP is found in different cancers, including B&#8208;cell lymphomas; however, the functional relevance has not been fully elucidated (Akyurek et&#160;al, 2006).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>3666</offset>
      <text>Diffuse large B&#8208;cell lymphoma (DLBCL) is the most common aggressive B&#8208;cell lymphoma in adults (Shaffer et&#160;al, 2012). The majority of patients achieve a remission of their disease after first&#8208;line immunochemotherapy, which typically includes vinca alkaloids and checkpoint inducing agents such as anthracyclines, but 10% of patients are upfront refractory. Notably, about one&#8208;third of initially treatment&#8208;responsive tumors eventually recur or become refractory to conventional therapy (Martelli et&#160;al, 2013), indicating the urgent need to develop more specific targeted therapies. While a number of risk factors for aggressive disease as well as adverse genetic profiles and histologic categories have been defined (Ziepert et&#160;al, 2010; Shaffer et&#160;al, 2012; Pasqualucci, 2013), the molecular mechanisms of treatment resistance and escape from mitotic cell death remain obscure.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>4557</offset>
      <text>In this study, we set out to investigate the role of DUBs in the regulation of mitotic cell fate decisions. These studies revealed a mitosis&#8208;specific function for the ubiquitin&#8208;specific protease 9X (USP9X), which we show to deubiquitylate and stabilize XIAP in order to promote mitotic survival. We demonstrate that loss of this anti&#8208;apoptotic pathway sensitizes cells to spindle poison&#8208;induced mitotic cell death independent of their MCL1 status and show that overexpression of USP9X and concomitant high expression of XIAP determine adverse prognosis and treatment resistance in human aggressive B&#8208;cell lymphomas.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>5183</offset>
      <text>Results and Discussion</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>5206</offset>
      <text>To begin assessing the role of deubiquitylation in mitotic control, we analyzed cell cycle profiles of different USP family DUBs. This approach identified a significant enrichment of USP9X in mitotic cells (Fig&#160;1A). USP9X is involved in fundamental processes such as pre&#8208;implantation development and is considered to particularly enhance cell survival by stabilizing different pro&#8208;survival substrates such as &#946;&#8208;catenin and the pro&#8208;survival BCL2 family member MCL1 (Taya et&#160;al, 1999; Murray et&#160;al, 2004; Sacco et&#160;al, 2010; Schwickart et&#160;al, 2010; Vucic et&#160;al, 2011). While these pro&#8208;survival activities have not been shown to occur in a cell cycle&#8208;dependent manner, USP9X demonstrates mitotic activity as evidenced by its role in regulating chromosome alignment and segregation by means of targeting the inhibitor of apoptosis protein (IAP) family member survivin and Aurora B to centromeres (Vong et&#160;al, 2005). However, this mechanism coordinates proper chromosome division rather than cell survival. We therefore reasoned that USP9X might exert mitotic pro&#8208;survival activity by stabilizing other IAP family members than survivin. To investigate this possibility, we analyzed the stability of different IAP proteins under the condition of RNAi&#8208;mediated USP9X knockdown. We found that XIAP was the only candidate that displayed significant loss of mitotic expression in USP9X&#8208;silenced cells that was restored upon treatment with the proteasome inhibitor MG132, thus indicating a role for USP9X in proteasome&#8208;dependent mitotic stabilization of XIAP (Fig&#160;1B and Appendix&#160;Fig S1A and B). In further support of this notion, we found that both XIAP and USP9X display parallel accumulation in mitosis (Fig&#160;1A).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>6941</offset>
      <text>USP9X binds, deubiquitylates, and stabilizes XIAP in mitosis</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7002</offset>
      <text>Immunoblot analysis of HeLa cells using the indicated antibodies that were synchronized in G1/S phase using a double thymidine block or in mitosis using sequential thymidine and nocodazole treatment and collected at the given time points.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7241</offset>
      <text>Immunoblot analysis of HeLa cells that were transfected with siRNA oligonucleotides as indicated and left untreated or synchronized in mitosis using sequential thymidine and nocodazole treatment.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7437</offset>
      <text>Co&#8208;immunoprecipitation of XIAP and endogenous USP9X in HEK 293T cells that were transfected with FLAG&#8208;tagged XIAP or empty vector (EV) and synchronized in mitosis using nocodazole or left untreated.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7640</offset>
      <text>Co&#8208;immunoprecipitation of XIAP and endogenous USP9X in HEK 293T cells that were treated as in (C), but with additional transfection of the FLAG&#8208;tagged XIAP single amino acid mutants G188R and G188E. Only mitotic samples are shown. The asterisk denotes ubiquitylated forms of XIAP.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7925</offset>
      <text> In vivo ubiquitylation of XIAP in HeLa cells that were infected with the indicated expression constructs carrying FLAG&#8208;tagged XIAP and transfected with siRNA oligonucleotides as specified. Cells were synchronized in mitosis using sequential thymidine/nocodazole treatment, as indicated. Subsequent to treatment with MG132, whole&#8208;cell extracts (WCE) were prepared and ubiquitylated XIAP was isolated by anti&#8208;FLAG immunoprecipitation (IP) under denaturing conditions.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>8398</offset>
      <text>Immunoblot analysis of NIH 3T3 cells that were transfected with expression constructs for USP9XWT or the catalytically inactive mutant USP9XC1556S. The band in the EV control lane of the anti&#8208;V5 panel marks an unspecific band produced by the antibody.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>8652</offset>
      <text>Immunoblot analysis of HeLa cells using antibodies to the indicated endogenous proteins that were synchronized in mitosis using thymidine/nocodazole and treated with DMSO or the USP9X inhibitor WP1130 as indicated.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>8867</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>8870</offset>
      <text> Source data are available online for this figure. </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>8922</offset>
      <text>To further substantiate a role for USP9X in regulating XIAP in mitosis, we tested direct interaction of USP9X and XIAP. Indeed, co&#8208;immunoprecipitation studies under semi&#8208;endogenous conditions identified preferential interaction of XIAP with USP9X in mitosis (Fig&#160;1C and Appendix&#160;Fig S1C). Likewise, immunofluorescence studies revealed co&#8208;localization of USP9X and XIAP in either prometaphase or metaphase cells (Appendix&#160;Fig S1D). Moreover, the interaction of USP9X and XIAP increased upon prolonged exposure to taxol, which leads to a gradual mitotic enrichment of cells (Appendix&#160;Fig S1E). Direct interaction of USP9X with XIAP was further verified in&#160;vitro using purified proteins (Fig&#160;EV1A). Notably, XIAP specifically interacted with the USP9X fragment containing the active cystein protease site (Fig&#160;EV1A).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>9749</offset>
      <text> USP9X interacts with XIAP in a direct manner and its active site binds to the BIR2 domain of XIAP via glycine 188</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>9864</offset>
      <text> In vitro co&#8208;immunoprecipitation of GST&#8208;purified XIAP with in&#160;vitro translated fragments of human USP9X with F2 containing the active site (aa 1556&#8211;1902).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10026</offset>
      <text>Co&#8208;immunoprecipitation of either full&#8208;length or different fragments of FLAG&#8208;tagged XIAP with endogenous USP9X from HEK 293T cells that were transfected with the indicated expression constructs and synchronized in mitosis using nocodazole.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10271</offset>
      <text>Immunoblot analyses of HeLa cells that were transfected with the indicated WT and mutant XIAP expression constructs and treated with cycloheximide (CHX) for the times specified.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10449</offset>
      <text>Co&#8208;immunoprecipitation of FLAG&#8208;tagged XIAP with endogenous USP9X from HEK 293T cells that were treated with BV6 as specified and nocodazole for 12&#160;h.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10604</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10607</offset>
      <text> Source data are available online for this figure. </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>10659</offset>
      <text>Mapping studies using different deletion mutants narrowed the USP9X binding motif to the BIR2 and BIR3 domains of XIAP (aa152&#8211;323) (Fig&#160;EV1B). This sequence contains a glycine residue at position 188, whose germline mutation marks a causative molecular aberration of the X&#8208;linked lymphoproliferative syndrome type 2 (XLP&#8208;2), which features low or instable expression of XIAP and premature apoptosis of lymphocytes in response to different stimuli (Rigaud et&#160;al, 2006). Two respective mutations of XIAP at G188 have been described, G188E and G188R, which diminish XIAP expression levels in patient B cells (Marsh et&#160;al, 2009; Gifford et&#160;al, 2014). Indeed, we found that both mutations abolish binding of XIAP to USP9X, and both XIAP mutants demonstrate reduced stability in mitosis (Figs&#160;1D and EV1C). Moreover, SMAC mimetics, which are known to interfere with protein binding of XIAP via its BIR2 domain (Krieg et&#160;al, 2009; Damgaard et&#160;al, 2013), disrupted the interaction of USP9X to XIAP (Fig&#160;EV1D). Together, these data suggest a role of Gly188 within the BIR2 domain as the binding site of XIAP for USP9X.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>11783</offset>
      <text>We next investigated whether mitotic stability of XIAP directly relies on the deubiquitylating activity of USP9X. To this end, we performed deubiquitylation assays using mitotic cells under conditions of both USP9X knockdown and forced USP9X expression. Indeed, ubiquitylation of XIAP was substantially increased upon silencing or chemical inhibition of USP9X (Figs&#160;1E and EV2A) in mitotic cells, while forced expression of USP9X attenuated XIAP ubiquitylation (Fig&#160;EV2A). In line with this, we found the overall deubiquitylation activity of USP9X to be elevated in mitosis (Fig&#160;EV2B). Notably, staining with linkage&#8208;specific ubiquitin antibodies revealed that USP9X removes K48&#8208;linked ubiquitin chains from XIAP (Fig&#160;EV2C). Moreover, we found that ubiquitylation of the XIAPG188R mutant is substantially increased in mitotic cells as compared to WT XIAP and that mitotic ubiquitylation of XIAPG188E remained unaffected upon USP9X overexpression (Fig&#160;EV2D and E). These findings support the notion that the reduced stability of these mutants may result from their inability to bind USP9X with the consequence of increased ubiquitylation and degradation, and may have implications in the pathophysiology of the XLP&#8208;2 syndrome. In a complimentary approach, we found that a catalytically inactive USP9X mutant (USP9XC1556S) was unable to confer stability to XIAP in mitotic cells (Fig&#160;1F). Likewise, addition of the USP9X inhibitor WP1130 destabilized XIAP in mitotic cells (Fig&#160;1G).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>13277</offset>
      <text> USP9X deubiquitylates XIAP&#8208;WT, but not XIAP&#8208;G188R or XIAP&#8208;G188E, in mitosis</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>13360</offset>
      <text> In vivo ubiquitylation of XIAP in HEK 293T cells that were co&#8208;transfected with the indicated expression constructs, synchronized in mitosis using nocodazole, and treated with MG132 prior to harvesting. The USP9X inhibitor WP1130 was added for 2&#160;h as specified. XIAP was isolated by streptavidin affinity purification (AP) using denaturing conditions.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>13715</offset>
      <text>HeLa cells were arrested in S phase with double thymidine block, released, and collected at the indicated time points. Deubiquitination activity was assessed by addition of HA&#8208;tagged dominant negative diubiquitin and following HA&#8208;IP under denaturing conditions.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>13981</offset>
      <text>Immunoblot analysis of in&#160;vivo ubiquitylated XIAP (prepared as in A) using K48&#8208; or K63&#8208;specific ubiquitin antibodies.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>14104</offset>
      <text> In vivo ubiquitylation of XIAPWT or XIAPG188R in HEK 293T cells that were co&#8208;transfected with the indicated expression constructs, synchronized in mitosis, and treated with MG132 as in (A). XIAPWT or XIAPG188R were isolated by anti&#8208;FLAG immunoprecipitation under denaturing conditions.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>14395</offset>
      <text> In vivo ubiquitylation of XIAPWT or XIAPG188E in HEK 293T cells that were co&#8208;transfected with the indicated expression constructs and treated as in (A). XIAPWT or XIAPG188E were isolated by streptavidin affinity purification under denaturing conditions.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>14652</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>14655</offset>
      <text> Source data are available online for this figure. </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>14707</offset>
      <text>We reasoned that USP9X deubiquitylates XIAP to regulate mitotic survival. To investigate this possibility, we silenced USP9X expression and analyzed cell death under conditions of prolonged taxol&#8208;induced mitotic arrest. Indeed, suppression of the USP9X&#8211;XIAP axis increased mitotic cell death in wild&#8208;type MEFs as evidenced by an increase of the sub&#8208;G1 fraction and a decrease of the mitotic cell population as well as by an increase of cleaved caspase&#8208;3 and loss of cyclin B1 expression (Fig&#160;2A and B). Importantly, Usp9X knockdown did not induce specific loss of the mitotic compartment in Xiap &#8722;/&#8722; cells, indicating that USP9X promotes mitotic survival directly via stabilization of XIAP (Fig&#160;2B). Of further notice, Xiap &#8722;/&#8722;, but not cIap2 &#8722;/&#8722;, cells demonstrate an increased overall sensitivity toward taxol exposure in the control setting, thus further emphasizing a role for XIAP in preventing mitotic apoptosis (Fig&#160;2A and B). A previous study suggested MCL1 as a cell cycle&#8208;independent substrate of USP9X (Schwickart et&#160;al, 2010). In addition, MCL1 has been shown to be ubiquitylated and degraded via APC/CCdc20 and SCFFbxw7 upon onset of mitosis (Harley et&#160;al, 2010; Inuzuka et&#160;al, 2011; Wertz et&#160;al, 2011). We therefore investigated the effect of Usp9X knockdown in Mcl1 &#8722;/&#8722; MEFs to rule out the possibility that USP9X mediates its mitosis&#8208;specific effects by stabilizing MCL1. Indeed, knockdown of Usp9X increased mitotic cell death in Mcl1 &#8722;/&#8722; cells to a similar extent as in WT MEFs, thus indicating independence of MCL1 (Fig&#160;2A and B). The elevated baseline apoptosis observed in Mcl1 &#8722;/&#8722; cells is likely attributable to elevated spontaneous apoptosis and higher sensitivity to infection procedures, which have been reported for these cells (Opferman et&#160;al, 2005). In line with these observations, neither USP9X overexpression nor USP9X knockdown affected expression levels of MCL1 in mitotically arrested cells (Figs&#160;1G and 2A). Finally, we investigated the impact of forced USP9X and XIAP expression as well as XIAP silencing on mitotic survival. In accordance with the results above, overexpression of either USP9X or XIAP protected cells from apoptosis, as visualized by a decrease of caspase&#8208;3 cleavage (Fig&#160;2C and D) and the reduction of the apoptotic index (Fig&#160;2E). By contrast, this effect was not observed upon expression of the USP9X binding&#8208;deficient XIAPG188R and XIAPG188E mutants, presumably because of their decreased mitotic stability (Fig&#160;EV1C). Likewise, loss of XIAP promoted cell death upon prolonged taxol&#8208;induced mitotic arrest (Fig&#160;2F).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>17340</offset>
      <text>USP9X stabilizes XIAP to antagonize mitotic cell death independent of MCL1</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>17415</offset>
      <text>Immunoblot analysis of WT, Xiap &#8722;/&#8722;, Mcl1 &#8722;/&#8722;, or cIap2 &#8722;/&#8722; mouse embryonic fibroblasts that were lentivirally infected with shRNA constructs directed against a non&#8208;relevant mRNA (Ctrl) or against Usp9X mRNA and treated with taxol as specified.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>17674</offset>
      <text>Two&#8208;dimensional cell cycle analysis (BrdU/PI) of cells described in (A). Sub&#8208;G1 and G2/M fractions of cells were quantified and averaged with two additional, independent experiments (n&#160;=&#160;3, &#177;&#160;SD; WT: **P&#160;=&#160;0.0016; ***P&#160;=&#160;0.0004; Mcl1 &#8722;/&#8722;: ***P&#160;=&#160;0.0003; **P&#160;=&#160;0.0017; cIap2 &#8722;/&#8722;: **P&#160;=&#160;0.0043, Student's t&#8208;test). Black bars exemplify shRNA Ctrl and white bars shRNA Usp9X samples.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>18082</offset>
      <text>Immunoblot analysis of HeLa cells transfected with a FLAG&#8208;tagged USP9X expression construct or empty vector (EV) and treated with taxol for the indicated times.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>18245</offset>
      <text>Immunoblot analysis of HeLa cells transfected with a FLAG&#8208;tagged XIAP expression construct or empty vector and treated as in (C).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>18377</offset>
      <text>Two&#8208;dimensional cell cycle analysis (BrdU/PI) of cells described in (C) and (D). Apoptotic indices represent ratios of sub&#8208;G1 to G1/S cells and are shown for analyses at the indicated time points (n = 3, &#177; SD). **P&#160;=&#160;0.0020; ***P&#160;=&#160;0.0004; Student's t&#8208;test.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>18646</offset>
      <text>Immunoblot analysis of HeLa cells that were transfected with siRNA oligonucleotides directed against a non&#8208;relevant mRNA (Ctrl) or against Xiap mRNA and treated with taxol as specified.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>18834</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>18837</offset>
      <text> Source data are available online for this figure. </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>18889</offset>
      <text>Together, the above results demonstrate that USP9X confers mitotic stability to XIAP during the activated SAC by means of interaction with XIAP at glycine residue 188 and subsequent specific deubiquitylation, thereby mediating mitotic survival independent of MCL1. Of notice, unchallenged XIAP&#8208;deficient mice are viable and do not show any substantial histopathological abnormalities (Harlin et&#160;al, 2001; Olayioye et&#160;al, 2005). Our results suggest that XIAP may be of particular relevance in a cellular environment that challenges mitotic survival.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>19442</offset>
      <text>The evasion of apoptosis is particularly pertinent to B&#8208;cell lymphomagenesis, where in the cells of origin, DNA double&#8208;strand breaks are a physiological process during the formation and revision of antigen receptors, requiring efficient means to eliminate cells with persistent DNA damage. In addition, agents like vinca alkaloids that target the mitotic checkpoint are key components of current first&#8208;line lymphoma treatment protocols (Shaffer et&#160;al, 2012; Wilson, 2013). We therefore investigated whether the USP9X&#8211;XIAP circuit is involved in the pathophysiology and therapy resistance of B&#8208;cell lymphomas. This effort was further fostered by different lymphoma aCGH and NGS studies that suggest overexpression and copy number gains of USP9X in human diffuse large B&#8208;cell lymphoma (DLBCL) (Bea et&#160;al, 2005; Morin et&#160;al, 2013).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>20286</offset>
      <text>First, we investigated the role of USP9X&#8208;mediated stabilization of XIAP in the context of B&#8208;cell lymphoma maintenance in&#160;vivo. For these studies, we chose a syngeneic approach using primary E&#956;&#8208;Myc B&#8208;cell lymphoma&#8208;derived cells. The E&#956;&#8208;Myc mouse model is well established to study alterations in apoptotic pathways that drive B&#8208;cell lymphoma development and maintenance (Adams et&#160;al, 1985; Vaux et&#160;al, 1988; Eischen et&#160;al, 1999). Given the short latency of this approach, we chose to silence either Usp9X or Xiap (Fig&#160;3A), which would be predicted to delay disease onset. Indeed, lymphoma onset was substantially delayed in mice receiving either Usp9X&#8208; or Xiap&#8208;silenced cells (Fig&#160;3B and C), in line with an in&#160;vitro analysis of the respective cells (Appendix&#160;Fig S2A). At necropsy, lesions were confirmed to be B&#8208;cell lymphoma, and increased apoptosis as well as reduced infiltration of lymph nodes and bone marrow was present in both Usp9X&#8208; and Xiap&#8208;silenced specimens (Fig&#160;3D and E, and Appendix&#160;Fig S2B and C). In a complimentary approach using PET analysis, we found significantly reduced tumor burden of mice receiving Usp9X&#8208; or Xiap&#8208;silenced cells 2&#160;weeks after lymphoma cell injection (Fig&#160;3F). Of notice, simultaneous knockdown of Usp9X and Xiap did not increase survival as compared to the single Xiap knockdown, indicating that USP9X functions via XIAP to promote lymphoma survival and growth in this model (Appendix&#160;Fig S2D and E). Importantly, response to vincristine treatment was substantially increased in mice receiving Usp9X or Xiap knockdown cells (Fig&#160;3G and H, and Appendix&#160;Fig S2F). These data suggest that USP9X&#8208;mediated stabilization of XIAP promotes growth, survival, and resistance to spindle poisons in B&#8208;cell lymphoma.</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>22081</offset>
      <text>USP9X and XIAP promote lymphoma growth and resistance to spindle poisons in&#160;vivo </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>22164</offset>
      <text>Immunoblot analysis of sorted E&#956;&#8208;Myc lymphoma cells that were retrovirally transduced with the indicated IRES&#8208;GFP shRNA constructs.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>22301</offset>
      <text>Kaplan&#8211;Meier survival curves of mice that were injected intravenously with syngeneic E&#956;&#8208;Myc lymphoma cells transduced with the indicated shRNA constructs as described in (A). Prior to injection, cells were sorted for viability (propidium iodide negative) and GFP positivity (sh_Ctrl, black, n&#160;=&#160;6; sh_USP9X, gray, n&#160;=&#160;5). *P&#160;=&#160;0.0293; Mantel&#8211;Cox test.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>22666</offset>
      <text>Kaplan&#8211;Meier survival curves of mice that were injected with syngeneic E&#956;&#8208;Myc lymphoma cells transduced with the indicated shRNA constructs as described in (A) and treated as in (B) (sh_Ctrl, black, n&#160;=&#160;6; sh_XIAP, gray, n&#160;=&#160;6). **P&#160;=&#160;0.0020; Mantel&#8211;Cox test.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>22939</offset>
      <text>Histopathology of representative lymph nodes derived from mice shown in (B) to visualize histomorphology by hematoxylin/eosin (H&amp;E), B&#8208;cell origin (B220), and spontaneous apoptosis (cleaved caspase&#8208;3) in&#160;situ. Scale bars denote 50&#160;&#956;m and 20&#160;&#956;m for insets.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>23204</offset>
      <text>Histopathology of representative lymph nodes derived from mice shown in (C) which were stained as described in (D). Scale bars denote 50&#160;&#956;m and 20&#160;&#956;m for insets.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>23370</offset>
      <text>Mean tumor burden in animals injected with E&#956;&#8208;Myc lymphoma cells modified as in (B) and (C), 15&#160;days after injection, assessed by PET imaging (four animals per group) (&#177; SD). **P&#160;=&#160;0.0025; ***P&#160;=&#160;0.0003, Student's t&#8208;test.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>23603</offset>
      <text>Representative PET images of animals, injected with E&#956;&#8208;Myc lymphoma cells modified as in (B) and (C), 15&#160;days after injection (pre&#8208;treatment) and 3&#160;days following intraperitoneal vincristine administration (post&#8208;treatment). Bone marrow infiltration, representative for systemic lymphoma manifestation, is indicated by a blue asterisk.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>23947</offset>
      <text>Mean change in standardized 18FDG uptake of ROI between pre&#8208; and post&#8208;treatment imaging corrected for initial tumor burden (sh_Ctrl, black, n&#160;=&#160;6; sh_Usp9X, white, n&#160;=&#160;8; sh_Xiap, gray, n&#160;=&#160;8). Within the sh_Usp9X and sh_Xiap groups, all animals lived up to control imaging, while two of eight animals of the sh_Ctrl group had to be sacrificed prematurely because they had reached the predefined criteria of maximum tumor burden. These animals had to be excluded from final analysis, suggesting an underestimation of the actual effect. Data were obtained from two independent experiments (&#177;&#160;SD). ****P&#160;&lt;&#160;0.0001; *P&#160;=&#160;0.0167, Student's t&#8208;test</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>24607</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>24610</offset>
      <text> Source data are available online for this figure. </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>24662</offset>
      <text>We next investigated the role of the USP9X&#8211;XIAP axis in human DLBCL cell lines.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>24744</offset>
      <text>To this end, we first specified human DLBCL cell lines with either low (SuDHL 4, SuDHL 6, Oci&#8208;Ly 3) or high (RIVA, HT, Oci&#8208;Ly 10) USP9X expression and found associated high expression of XIAP (Fig&#160;4A). Notably, RIVA, HT, and Oci&#8208;Ly 10 cells demonstrate increased resistance toward taxol treatment (Fig&#160;4B). To investigate a direct functional involvement of USP9X, we silenced USP9X in these cells and treated with either taxol or doxorubicin, which typically induces G2/M arrest in tumor cells via activation of the DNA damage response. Indeed, USP9X knockdown resolved resistance to taxol or doxorubicin in USP9X/XIAP high&#8208;expressing cells (HT, RIVA) as demonstrated by caspase&#8208;3 cleavage, while the USP9X/XIAP low&#8208;expressing cell lines SuDHL 4 and SuDHL 6 were not significantly affected (Figs&#160;4C and EV3A). Similar results were observed in a complementary approach using the USP9X inhibitor WP1130 in SuDHL 6, Oci&#8208;Ly 3, HT, and Oci&#8208;Ly 10 cells treated with taxol (Kapuria et&#160;al, 2010; Wang et&#160;al, 2014; Figs&#160;4D and EV3B).</text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>25791</offset>
      <text>USP9X is overexpressed in DLBCL to promote survival and resistance to anti&#8208;tubulin chemotherapeutics via mitotic stabilization of XIAP</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>25928</offset>
      <text>Immunoblot analyses of different human DLBCL lines using antibodies to the indicated proteins.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>26023</offset>
      <text>FACS analysis (propidium iodide, PI) of USP9X high&#8208; and low&#8208;expressing DLBCL cells shown in (A) to determine cell survival. Cells were treated with taxol and collected at the specified time points. PI&#8208;negative cells are indicated relative to time point 0 (n&#160;=&#160;3, &#177;&#160;SD).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>26303</offset>
      <text>Immunoblot analyses of the indicated DLBCL cell lines that were lentivirally transduced with IRES&#8208;GFP shRNA constructs against USP9X or a non&#8208;relevant mRNA, FACS sorted for GFP+ PI&#8722; cells and exposed to taxol for the indicated periods of time. The quantification of cleaved caspase&#8208;3 (CC3) at the 24&#160;h post&#8208;taxol treatment time point from four independent experiments is quantified in the graph on the right side and normalized to control shRNA (&#177; SD). **P&#160;=&#160;0.0099, Student's t&#8208;test.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>26804</offset>
      <text>Immunoblot analyses of the indicated DLBCL cell lines that were exposed to taxol for the indicated periods of time. Three hours before collecting, WP1130 at a concentration of 5&#160;&#956;M or DMSO was added as specified.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>27019</offset>
      <text>FACS analysis (propidium iodide (PI) uptake) of DLBCL cell lines treated with taxol and/or the SMAC mimetic BV6 as indicated. Results displayed are from three independent experiments (n&#160;=&#160;3, &#177;&#160;SD). ***P&#160;=&#160;0.00085; **P&#160;=&#160;0.00529; Student's t&#8208;test.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>27276</offset>
      <text>Collective assessment of USP9X and XIAP expression determined by immunohistochemistry in tissue microarrays (TMA) derived from a patient cohort representing 121 evaluable human CD20+ aggressive B&#8208;cell lymphomas. High USP9X expression was identified in 37 cases (31%) and significantly correlated with high XIAP expression levels (**P&#160;=&#160;0.004; Student's t&#8208;test).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>27644</offset>
      <text>Expression data derived from (E) were correlated with clinical follow&#8208;up. Within a cohort of 58 patients receiving vincristine&#8208;containing chemotherapy (CHOP regimen: cyclophosphamide, doxorubicin, vincristine, prednisone) without the addition of the anti&#8208;CD20 antibody rituximab (left panel), overexpression of USP9X and XIAP (n&#160;=&#160;14, straight line) was associated with a significantly shortened event&#8208;free survival (EFS) as compared to all remaining patients (n&#160;=&#160;44, dotted line) (*P&#160;=&#160;0.050; log&#8208;rank test). Within a cohort of 63 patients receiving the CHOP regimen with the addition of the anti&#8208;CD20 antibody rituximab, overexpression of USP9X and XIAP (n&#160;=&#160;14, straight line) was not associated with a shortened event&#8208;free survival (EFS) as compared to all remaining patients (n&#160;=&#160;49, dotted line) (P&#160;=&#160;0.454).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>28486</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>28489</offset>
      <text> Source data are available online for this figure. </text>
    </passage>
    <passage>
      <infon key="type">fig_title_caption</infon>
      <offset>28541</offset>
      <text>Mitotic stabilization of XIAP by USP9X mediates resistance to spindle poisons</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>28619</offset>
      <text>Immunoblot analyses of the indicated DLBCL cell lines that were lentivirally transduced with IRES&#8208;GFP shRNA constructs against USP9X or a non&#8208;relevant mRNA, FACS sorted for GFP+ PI&#8722; cells and exposed to doxorubicin for the indicated periods of time.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>28875</offset>
      <text>Immunoblot analyses of the indicated DLBCL cell lines that were exposed to taxol for the indicated periods of time. Two hours before collecting, WP1130 at a concentration of 5&#160;&#956;M or DMSO was added as specified.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>29088</offset>
      <text>FACS analysis (propidium iodide (PI) uptake) of DLBCL cell lines treated with taxol and/or the SMAC mimetic BV6 as indicated. Results displayed are from three independent experiments each (n&#160;=&#160;3, &#177;&#160;SD). **P&#160;=&#160;0.00643; Student's t&#8208;test.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>29332</offset>
      <text>Immunoblot analyses of the indicated DLBCL cell lines that were treated with taxol or the SMAC mimetic BV6 as indicated.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>29453</offset>
      <text>  </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>29456</offset>
      <text> Source data are available online for this figure. </text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>29508</offset>
      <text>X&#8208;linked inhibitor of apoptosis protein is naturally inhibited by SMAC (second mitochondria&#8208;derived activator of caspases)/DIABLO (direct inhibitor of apoptosis&#8208;binding protein with low isoelectric point) binding, which results in the release and activation of caspase&#8208;9 (Du et&#160;al, 2000). Small&#8208;molecule inhibitors mimicking this effect, that is, SMAC mimetics, have shown potent apoptosis&#8208;inducing activity in cell culture, animal models, and early clinical trials (Fulda &amp; Vucic, 2012). We therefore treated DLBCL cells with the SMAC mimetic BV6 and/or taxol. Indeed, we observed significant potentiation of taxol&#8208;induced cell death in USP9X/XIAP high/taxol&#8208;insensitive (HT, Oci&#8208;Ly 10, RIVA) cells, while this effect was not present in USP9X/XIAP low/taxol&#8208;sensitive (SuDHL 4, SuDHL 6, Oci&#8208;Ly 3) cells (Figs&#160;4E and EV3C). SMAC mimetics have been shown to induce degradation of cIAP1/2 (Li et&#160;al, 2004; Varfolomeev et&#160;al, 2007; Vince et&#160;al, 2007). To rule out the possibility that increased sensitivity of USP9X/XIAP high&#8208;expressing cells to BV6 results from increased cIAP1/2 degradation, we analyzed cIAP1/2 levels in BV6&#8208;treated SuDHL 6 and HT cells. Indeed, USP9X/XIAP high&#8208;expressing HT cells demonstrated only marginal changes of cIAP1/2, in explicit contrast to USP9X/XIAP low&#8208;expressing SuDHL 6 cells, while XIAP was readily destabilized (Fig&#160;EV3D). These findings further underscore a role of XIAP as the relevant USP9X substrate for mitotic survival in B&#8208;cell lymphoma.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>31027</offset>
      <text>To further extend our studies on the role of the USP9X&#8211;XIAP axis in aggressive human B&#8208;cell lymphoma, we analyzed USP9X/XIAP expression by immune histochemistry (IHC) in tissue microarrays (TMAs) assembled from a cohort of 121 human CD20+ aggressive B&#8208;cell lymphoma samples. These specimens were derived from the RICOVER&#8208;60 trial of the German High Grade Non&#8208;Hodgkin's Lymphoma study Group (DSHNHL) and shown to be representative of the full study population (Appendix&#160;Table&#160;S1). In the RICOVER&#8208;60 trial, patients were randomized to receive six or eight cycles of a chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) alone or in combination with the CD20&#8208;specific antibody rituximab (Pfreundschuh et&#160;al, 2008). Indeed, IHC analyses revealed high expression of USP9X in 37 patients (31%), which significantly correlated with high XIAP expression (P&#160;=&#160;0.004) (Fig&#160;4F). We further evaluated whether high USP9X/XIAP expression correlates with clinical outcome in the patient cohort indicated above. When treated with CHOP without rituximab (n&#160;=&#160;58), patients with USP9X/XIAP overexpression had a significantly lower 2&#8208;year event&#8208;free survival [36% (95% CI 9&#8211;64%)] in a univariate analysis compared to all other patients [71% (95% CI 57&#8211;84%; *P&#160;=&#160;0.050; Fig&#160;4G)]. By contrast, no significant difference was observed between the two groups when treated with CHOP and the anti&#8208;CD20 antibody rituximab [2&#8208;year event&#8208;free survival of 67% (95%&#8208;CI 43&#8211;94%) vs. 63% (95%&#8208;CI 50&#8211;77%) for all other patients (P&#160;=&#160;0.454)] (Fig&#160;4G). While rituximab's mechanism of action is still not fully understood, a large body of evidence suggests complement&#8208;mediated cytotoxicity (CMC) and antibody&#8208;dependent cellular cytotoxicity (ADCC) as major means, rather than checkpoint&#8208;induced apoptosis (Weiner, 2010).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>32915</offset>
      <text>In this analysis, USP9X/XIAP double high cases were compared to the remaining cases (including cases with low USP9X and high XIAP) because these cases reflect the constellation where elevated XIAP is predicted to result from mitotic USP9X&#8208;mediated stabilization of XIAP. Other USP9X&#8208;independent causes of elevated XIAP levels likely exist, which would however not reflect the situation in which DLBCL cells depend on the mitotic activity of the USP9X&#8211;XIAP axis. Likewise, elevated USP9X expression without concomitant XIAP stabilization would not reflect mitosis&#8208;specific activation of this new mechanism. This observation thus further argues for a specific role of the USP9X&#8211;XIAP axis in mediating resistance against checkpoint activating agents and spindle poisons.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>33693</offset>
      <text>Diffuse large B&#8208;cell lymphoma can be categorized into three subtypes termed germinal&#8208;center B&#8208;cell&#8208;like (GCB) DLBCL, activated B&#8208;cell&#8208;like (ABC) DLBCL, and primary mediastinal B&#8208;cell lymphoma (PMBL), according to their gene expression profiles, which depend on different oncogenic pathways (Frick et&#160;al, 2011). The ABC subtype has been associated with unfavorable prognosis and increased resistance to standard treatment strategies (Frick et&#160;al, 2011). We therefore evaluated a large DLBCL gene profiling dataset with regard to USP9X expression in different subtypes (Lenz et&#160;al, 2008). This analysis however did not reveal a significant difference between USP9X overexpression in the ABC&#8208; or GCB&#8208;type DLBCL (Appendix&#160;Fig S3), in line with our respective analysis in DLBCL cell lines, which also did not detect a specific pattern of USP9X expression (ABC&#8208;type: RIVA, Oci&#8208;Ly 10, Oci&#8208;Ly 3; GCB&#8208;type: HT, SuDHL 4, SuDHL 6). We therefore suggest that USP9X/XIAP aberrations are not linked to either DLBCL subtype.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>34733</offset>
      <text>Together, our analyses in patient samples identify overexpression of USP9X/XIAP in a significant number of patients with CD20+ aggressive B&#8208;cell lymphoma and provide initial evidence that overexpression of USP9X/XIAP may serve as a prognostic marker in patients treated with DNA damaging agents and spindle poisons to define a subgroup of high risk and chemotherapy refractory patients, independent of the ABC/GCB classification. These insights may mark a framework from which to further investigate therapeutic approaches targeting USP9X and XIAP in patients with CD20+ aggressive B&#8208;cell lymphoma that display high USP9X/XIAP expression levels or spindle poison refractory disease. Our data further suggest that the addition of SMAC mimetics, which are currently under evaluation in early clinical trials, to spindle poison&#8208;containing chemotherapy regimens may be such an approach that warrants further investigation.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>35658</offset>
      <text>Materials and Methods</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>35680</offset>
      <text>Cell culture and drug treatments</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>35713</offset>
      <text>HeLa, Cos7, NIH 3T3, and HEK 293T were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal FBS (HEK 293T: 10% BS) and 1% penicillin/streptomycin (P/S), and Phoenix Eco cells were kept in the same medium without P/S. Mouse embryonic fibroblasts (MEFs) were maintained in DMEM containing 20% FBS, 1% nonessential amino acids, and 1% P/S. Mcl&#8208;1 &#8722;/&#8722; MEF, Xiap &#8722;/&#8722; MEF, and cIap2 &#8722;/&#8722; MEF were obtained by a material transfer agreement from the Walter and Eliza Hall Institute, Melbourne, Australia. The DLBCL lines HT, RIVA, SuDHL 4, and SuDHL 6 were cultured in RPMI&#8208;1640 with 20% FBS and 1% P/S Oci&#8208;Ly 3 and Oci&#8208;Ly 10 in IMDM with 20% FBS, 1% P/S, and 0.1% &#946;&#8208;mercaptoethanol. E&#956;&#8208;Myc cells were cultured in RPMI&#8208;1640 medium supplemented with FBS 10%, nonessential amino acids 1%, &#946;&#8208;mercaptoethanol 0.1%, and P/S 1%. Where indicated, the following drugs were used: MG132&#160;(10&#160;&#956;M), thymidine 2&#160;mM, nocodazole 400&#160;ng/ml, CHX (100&#160;&#956;g/ml), paclitaxel (500&#160;nM), WP1130 (10&#160;nM unless otherwise specified), doxorubicin (1&#160;&#956;M), RO&#8208;3306 (9&#160;&#956;M). For synchronization in mitosis, HeLa cells were treated with thymidine, if applicable 24&#160;h after siRNA transfection. Twenty&#8208;four hours later, thymidine was washed off and either nocodazole was added for another 12&#160;h or RO&#8208;3306 was added for 16&#160;h and then washed off, and cells were collected one hour later. All cells tested mycoplasma negative by a PCR detection method.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>37198</offset>
      <text>Biochemical methods</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>37218</offset>
      <text>Extract preparation, immunoprecipitation, and immunoblotting have previously been described (Bassermann et&#160;al, 2008; Fernandez&#8208;Saiz et&#160;al, 2013; Baumann et&#160;al, 2014). Cell lysis was performed in buffer containing glycerol 5%, Tris&#8211;HCl pH 7.5 50&#160;mM, NaCl 250&#160;mM, EDTA 1&#160;mM, NP40 0.1%, MgCl2 5&#160;mM, and protease inhibitors (PIN, TPCK, TLCK, NaVa, DTT, glycerol&#8208;bisphosphate). Lysis buffer for immunoprecipitation experiments contained Tris&#8211;HCl 50&#160;mM, NaCl 150&#160;mM, EDTA 1&#160;mM, Triton X&#8208;100 1%, and protease inhibitors. After immunoprecipitation, beads were washed once in lysis buffer and three times in low salt buffer (Tris&#8211;HCl pH 7.5 50&#160;mM, NaCl 100&#160;mM, and MgCl2 50&#160;mM). For assessment of DUB activity, HeLa cells were synchronized in S phase and released as described above. At the given time points, cells were harvested and lysed in DUB activity lysis buffer (Tris&#8211;HCl pH 7.4 50&#160;mM, MgCl2 5&#160;mM, sucrose 250&#160;mM, DTT 1&#160;mM, ATP 2&#160;mM) for 20&#160;min. Subsequently, equal amounts of total protein were incubated with human recombinant HA&#8208;ubiquitin&#8208;vinyl sulfone (Boston Biochem, # U&#8208;212) at a concentration of 5&#160;&#956;M or solvent at 37&#176;C for 30&#160;min and vortexed every 10&#160;min. Thereafter, SDS was added to 1% samples boiled at 95&#176;C for 5&#160;min and then incubated at room temperature for another 5&#160;min. Thereafter, HA immunoprecipitation was performed. Protein in&#160;vitro translations and GST protein purifications were essentially performed as described previously (Bassermann et&#160;al, 2008; Fernandez&#8208;Saiz et&#160;al, 2013; Baumann et&#160;al, 2014).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>38795</offset>
      <text>Antibodies</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>38806</offset>
      <text>The following antibodies were used: beta&#8208;actin (1:10,000, mouse), BIRC8 (mouse, Abnova # H00112401&#8208;B01), cIAP1/2, cleaved caspase&#8208;3&#8208;5A1E (1:300, rabbit, Cell Signaling #9664), CUL1 (1:500, mouse, Invitrogen #32&#8208;2400), cyclin A (1:1,000, mouse, Santa Cruz #sc&#8208;751), cyclin B1 (1:1,000, mouse, Cell Signaling #4138), cyclin E (1:1,000, mouse, kind gift of M. Pagano), FLAG (1:1,000, rabbit, Sigma #F7425), FLAG&#8208;M2 (1:1,000, mouse, Sigma #F3165), HA&#8208;16B12 (1:2,000, mouse, Covance #MMS&#8208;101P), human MCL1 (1:500, rabbit, BD Pharmingen #554103), murine MCL1 (1:1,000, rabbit, A&amp;D Serotec AHP1249), ML&#8208;IAP (mouse, Santa Cruz #sc&#8208;71592), NIAP (rabbit, Abcam #ab25968), PARP1/2 (1:1,000, rabbit, Santa Cruz #sc&#8208;7150), pHH3 (S10) (1:300, rabbit, Cell Signaling #9701), PLK1 (1:500, rabbit, Invitrogen #33&#8208;1700), survivin (1:3,000, rabbit, R&amp;D Systems #AF886), USP7 (rabbit, Bethyl Lab. #A300&#8208;033A), USP9X (1:4,000, rabbit, Bethyl Laboratories #A301&#8208;351A), USP10 (rabbit, Bethyl Lab. #A300&#8208;900A), USP24 (Proteintech Europe, #13126&#8208;1&#8208;AP), USP28 (rabbit, Bethyl Lab. #A300&#8208;898A), V5 (1:1,000, rabbit, Sigma #V8137), XIAP (1:1,000, mouse, BD Biosciences #610716), XIAP (1:1,000, rabbit, Cell Signaling #2042), and XIAP (1:1,000, R&amp;D Systems #AF8221).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>40082</offset>
      <text>Immunofluorescence</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>40101</offset>
      <text>For immunofluorescence microscopy, cells were grown on cover slips prior to fixation in ice&#8208;cold methanol at &#8722;20&#176;C for 10&#160;min. Primary antibodies were used as outlined above. Secondary antibodies (Alexa Fluor 488 rabbit and Alexa Flour 594 goat, Life Technologies) were used at a dilution of 1:1,000. Antibodies were diluted in IF Buffer (0.5% Tween&#8208;20 in PBS) and fixed cells mounted with ProLong(R) Gold antifade reagent with DAPI (Life Technologies). Images were taken using the laser&#8208;scanning confocal microscope FluoView FV10i (Olympus).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>40654</offset>
      <text>Transient transfections and lentiviral DNA transfer</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>40706</offset>
      <text>Transient transfection was performed using CaCl2 as before (Bassermann et&#160;al, 2008) and Lipofectamine 2000&#169; according to the manufacturer's description. For lentiviral shRNA transfer into mouse embryonic fibroblasts, Phoenix Eco cell&#8208;derived media were applied in four spin infections with Polybrene 8&#160;&#956;g/ml.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>41021</offset>
      <text>Plasmids, shRNA, and siRNAs</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>41049</offset>
      <text> USP9X and XIAP siRNAs were obtained from Thermo Scientific Dharmacon&#174; (Cat No. J&#8208;006099&#8208;09; Cat No. L&#8208;004098&#8208;00), and siRNA transfection was performed using HiPerFect&#169; Transfection Reagent (Qiagen). shRNAs against Xiap in plko&#8208;based vectors were a kind gift from L. Nilsson. shRNAs directed against murine Usp9X targeted the following 21mer sequence: 5&#8242;&#8208;GAT GAG GAA CCT GCA TTT CCA&#8208;3&#8242;.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>41456</offset>
      <text>Cell cycle analyses</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>41476</offset>
      <text>For BrdU incorporation and DNA content analysis, cells were pulsed with 10&#160;&#956;M BrdU (BD Biosciences) for 120&#160;min and stained according to a standard protocol thereafter. Two&#8208;dimensional flow cytometry was performed to detect fluorescein and PI. To quantify cell cycle distribution, the FlowJo software (Tree Star Inc, Stanford) was applied.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>41821</offset>
      <text>Studies in mice</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>41837</offset>
      <text>E&#956;&#8208;Myc lymphoma cells were infected with lentiviral IRES&#8208;GFP shRNA constructs directed against a non&#8208;relevant mRNA or against USP9X mRNA or XIAP mRNA together with IRES&#8208;linked GFP, sorted 48&#160;h thereafter, and injected into syngeneic C57BL (Harlan) recipient mice (5&#160;&#215;&#160;104 cells per mouse). Equally housed, fed, and bred female mice of same size and age (10&#160;weeks) were thereby randomly distributed into experimental groups. Mice were examined weekly by lymph node palpation. Disease state was defined by the presence of palpable lymph nodes. Time point of sacrifice was determined by an independent member of the mouse facility with no insight into experimental design. To assess cell immunophenotype and GFP content, single&#8208;cell suspensions were obtained by passing lymph nodes and bone marrow through 70&#8208;&#956;m cell strainers. In preparation for FACS and immunoblotting, erythrocytes were lysed using buffer containing NH4Cl 0.15&#160;M, HEPES 0.02&#160;M, and EDTA 0.1&#160;M. Samples for immunohistochemistry (IHC) were fixed in 5% PFA. Survival data in each approach were analyzed using the Kaplan&#8211;Meier method, applying the log&#8208;rank (Mantel&#8211;Cox) test for statistical significance. Animals were censored from analyses when sacrificed for non&#8208;tumor reasons. For the survival and tumor growth studies, a group size of at least five animals per condition was chosen, which allowed the detection of twofold differences in survival with a power of 0.89, assuming a two&#8208;sided test with a significance threshold &#945; of 0.05 and a standard deviation of less than 50% of the mean.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>43426</offset>
      <text>For treatment experiments, the mice of each group, regardless of clinical tumor signs, underwent PET analysis at day 15 after injection of E&#956;&#8208;Myc lymphoma cells. Hence, they were injected with vincristine 4&#160;&#956;g intraperitoneally and re&#8208;imaged 3&#160;days thereafter (day 18).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>43704</offset>
      <text>Experiments were performed in accordance with the local ethical guidelines and approved by the responsible regional authorities (Regierung von Oberbayern).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>43860</offset>
      <text>PET data analysis</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>43878</offset>
      <text>Analysis was performed using the Inveon Research workplace to semiquantitatively assess the accumulation of tracer in the tumor. Three&#8208;dimensional regions of interest (ROIs) were drawn manually around lesions, and a threshold algorithm (50% maximum intensity &#8211; minimum intensity) was applied to each ROI to obtain an intensity value from the area with the highest tumor activity. Mean values were taken from the lesions, and the same lesions in each mouse were analyzed pre&#8208; and post&#8208;treatment.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>44381</offset>
      <text>Background activity was determined by establishing two identically sized 3D ROIs in the spinal muscles below the kidneys.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>44503</offset>
      <text>For evaluation of tumor response to vincristine, mean change in 18FDG uptake was assessed and corrected for tumor burden at the time of treatment initiation.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>44661</offset>
      <text>Immunohistochemistry and tumor samples</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>44700</offset>
      <text>For immunohistochemistry, tissue sections were deparaffinized. Antigen retrieval was carried out by pressure cooking in citrate buffer (pH 6 or pH 9) for 10&#160;min. USP9X or XIAP was detected after an overnight incubation at 4&#176;C by the DAKO REAL Detection Kit (DAKO) according to the manufacturer's protocol. Immunohistochemical data were interpreted by a certified pathologist blinded to clinicopathological data. Slides were evaluated using the Axioplan 2 microscope (Zeiss, Goettingen, Germany). A semiquantitative score for was used to evaluate protein expression as follows: score 0: no expression, score 1: expression in &lt;&#160;10% of tumor cells, score 2: expression in &gt;&#160;10% of tumor cells, score 3: expression in &gt;&#160;50% of tumor cells. Tumor samples showing scores 0&#8211;1 were called USP9X/XIAP low, and samples exhibiting scores 2&#8211;3 were summarized as USP9X/XIAP high. All human specimens were processed with informed consent in compliance with the institutional review board at the Faculty of Medicine of the Technical University of Munich and conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>45887</offset>
      <text>Normalization and quantification of protein levels</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>45938</offset>
      <text>Protein concentrations of whole&#8208;cell extracts (WCE) were determined using a Bio&#8208;Rad DC protein assay (Lowry assay). For each experiment, equal amounts of WCE were separated by SDS&#8211;PAGE and analyzed by immunoblotting. Equal protein levels in each lane were confirmed by Ponceau S staining of the membrane and by immunoblotting proteins whose levels are typically not regulated in response to apoptosis or cell cycle progression (e.g., CUL1, &#946;&#8208;actin).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>46397</offset>
      <text>Statistical analyses</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>46418</offset>
      <text>An objective was to analyze the association of USP9X&#8211;XIAP overexpression with event&#8208;free survival (EFS) in elderly patients with CD20+ aggressive B&#8208;cell lymphoma, according to primary histology. EFS was defined as time from randomization to disease progression, start of salvage treatment, additional (unplanned) treatments, relapse, or death from any cause.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>46783</offset>
      <text>The association of USP9X&#8211;XIAP overexpression and outcome was tested by the log&#8208;rank test and graphically displayed via Kaplan&#8211;Meier curves. Two&#8208;year rates with 95% confidence intervals and P&#8208;values are presented. For comparison of patient characteristics for the groups with and without TMA material, Pearson's chi&#8208;square tests were performed. For comparison of the median age, Mann&#8211;Whitney U&#8208;test was used. A statistically significant difference was assumed for P&#160;&#8804;&#160;0.05. Statistical analyses were done with SPSS statistics version 20.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>47340</offset>
      <text>Other statistical analysis of results was performed by log&#8208;rank (Mantel&#8211;Cox) test, Student's t&#8208;test, or one&#8208;way ANOVA, as specified in the individual figure legends according to the assumptions of the test using GraphPad Prism software. The bars shown represent the mean&#160;&#177;&#160;standard deviation (SD). Murine outcome data were visualized by Kaplan&#8211;Meier curves, and survival analyses were performed using a log&#8208;rank test. The P&#8208;values are presented in figure legends where a statistically significant difference was found. *P&#160;&lt;&#160;0.05; **P&#160;&lt;&#160;0.01; ***P&#160;&lt;&#160;0.001.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>47919</offset>
      <text>Author contributions</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>47940</offset>
      <text>KE and FB conceived and designed the research; KE performed most of the experiments with crucial help from AR, JS, JK, AB, B&#8208;ST, FL, and VF&#8208;S; MP, LT, and WK provided the lymphoma samples which were analyzed by MR, BA, and AR; BAA and SF performed experiments using SMAC mimetics; KE, LJ, MR, BA, CJG, MU, VF&#8208;S, MP, LT, WK, SF, UK, PJ, CP, and FB analyzed results; FB coordinated this work and wrote the manuscript together with KE All authors discussed the results and commented on the manuscript.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>48445</offset>
      <text>Conflict of interest</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>48466</offset>
      <text>The authors declare that they have no conflict of interest.</text>
    </passage>
    <passage>
      <infon key="type">title_1_caption</infon>
      <offset>48526</offset>
      <text>The paper explained</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>48546</offset>
      <text>Problem</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>48554</offset>
      <text>Diffuse large B&#8208;cell lymphoma (DLBCL) is the most common type of malignant lymphoma in adults, making up approximately 30% to 35% of all cases. While the majority of DLBCL patients respond well to initial chemotherapy, about half of the responders eventually relapse and about 10% are refractory to initial treatment. Factors predicting response to chemotherapy are not well characterized.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>48946</offset>
      <text>Results</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>48954</offset>
      <text>We here identify USP9X as the deubiquitylase which mediates mitosis&#8208;specific stabilization of the anti&#8208;apoptotic protein XIAP. We show that upregulation of USP9X and consequently of XIAP promote mitotic survival and increased resistance to mitotic spindle poisons in diffuse large B&#8208;cell lymphoma. Inactivation of both proteins sensitizes DLBCL cells to spindle poison&#8208;induced apoptosis. Furthermore, patients with high USP9X/XIAP expression demonstrate significantly reduced event&#8208;free survival after chemotherapeutic treatment.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>49494</offset>
      <text>Impact</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>49501</offset>
      <text>Overexpression of USP9X and XIAP is identified as a predictive biomarker for chemotherapy resistance in aggressive B&#8208;cell lymphoma. Targeting of USP9X or XIAP in USP9X/XIAP&#8208;overexpressing and/or chemotherapy refractory tumors may be a promising approach to improve survival of DLBCL patients.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>49798</offset>
      <text>Supporting information</text>
    </passage>
    <passage>
      <infon key="type">title</infon>
      <offset>49821</offset>
      <text>References</text>
    </passage>
    <passage>
      <infon key="volume">318</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">538</infon>
      <infon key="pub-id_pmid">3906410</infon>
      <infon key="fpage">533</infon>
      <infon key="year">1985</infon>
      <infon key="type">ref</infon>
      <offset>49832</offset>
      <text>The c&#8208;myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice</text>
    </passage>
    <passage>
      <infon key="volume">107</infon>
      <infon key="source">Cancer</infon>
      <infon key="lpage">1851</infon>
      <infon key="pub-id_pmid">16983704</infon>
      <infon key="fpage">1844</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>49935</offset>
      <text>Expression of inhibitor of apoptosis proteins in B&#8208;cell non&#8208;Hodgkin and Hodgkin lymphomas</text>
    </passage>
    <passage>
      <infon key="volume">134</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">267</infon>
      <infon key="pub-id_pmid">18662541</infon>
      <infon key="fpage">256</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>50029</offset>
      <text>The Cdc14B&#8208;Cdh1&#8208;Plk1 axis controls the G2 DNA&#8208;damage&#8208;response checkpoint</text>
    </passage>
    <passage>
      <infon key="volume">1843</infon>
      <infon key="source">Biochim Biophys Acta</infon>
      <infon key="lpage">162</infon>
      <infon key="pub-id_pmid">23466868</infon>
      <infon key="fpage">150</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>50110</offset>
      <text>The ubiquitin proteasome system &#8211; implications for cell cycle control and the targeted treatment of cancer</text>
    </passage>
    <passage>
      <infon key="volume">20</infon>
      <infon key="source">Nat Med</infon>
      <infon key="lpage">1409</infon>
      <infon key="pub-id_pmid">25419709</infon>
      <infon key="fpage">1401</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>50219</offset>
      <text>Disruption of the PRKCD&#8208;FBXO25&#8208;HAX&#8208;1 axis attenuates the apoptotic response and drives lymphomagenesis</text>
    </passage>
    <passage>
      <infon key="volume">106</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">3190</infon>
      <infon key="pub-id_pmid">16046532</infon>
      <infon key="fpage">3183</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>50328</offset>
      <text>Diffuse large B&#8208;cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene&#8208;expression&#8208;based survival prediction</text>
    </passage>
    <passage>
      <infon key="volume">104</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">780</infon>
      <infon key="pub-id_pmid">11257230</infon>
      <infon key="fpage">769</infon>
      <infon key="year">2001</infon>
      <infon key="type">ref</infon>
      <offset>50488</offset>
      <text>Structural basis of caspase&#8208;7 inhibition by XIAP</text>
    </passage>
    <passage>
      <infon key="volume">46</infon>
      <infon key="source">Mol Cell</infon>
      <infon key="lpage">758</infon>
      <infon key="pub-id_pmid">22607974</infon>
      <infon key="fpage">746</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>50539</offset>
      <text>The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity</text>
    </passage>
    <passage>
      <infon key="volume">5</infon>
      <infon key="source">EMBO Mol Med</infon>
      <infon key="lpage">1295</infon>
      <infon key="pub-id_pmid">23818254</infon>
      <infon key="fpage">1278</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>50635</offset>
      <text>Disease&#8208;causing mutations in the XIAP BIR2 domain impair NOD2&#8208;dependent immune signalling</text>
    </passage>
    <passage>
      <infon key="volume">388</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">304</infon>
      <infon key="pub-id_pmid">9230442</infon>
      <infon key="fpage">300</infon>
      <infon key="year">1997</infon>
      <infon key="type">ref</infon>
      <offset>50729</offset>
      <text>X&#8208;linked IAP is a direct inhibitor of cell&#8208;death proteases</text>
    </passage>
    <passage>
      <infon key="volume">102</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">42</infon>
      <infon key="pub-id_pmid">10929711</infon>
      <infon key="fpage">33</infon>
      <infon key="year">2000</infon>
      <infon key="type">ref</infon>
      <offset>50792</offset>
      <text>Smac, a mitochondrial protein that promotes cytochrome c&#8208;dependent caspase activation by eliminating IAP inhibition</text>
    </passage>
    <passage>
      <infon key="volume">13</infon>
      <infon key="source">Genes Dev</infon>
      <infon key="lpage">2669</infon>
      <infon key="pub-id_pmid">10541552</infon>
      <infon key="fpage">2658</infon>
      <infon key="year">1999</infon>
      <infon key="type">ref</infon>
      <offset>50910</offset>
      <text>Disruption of the ARF&#8208;Mdm2&#8208;p53 tumor suppressor pathway in Myc&#8208;induced lymphomagenesis</text>
    </passage>
    <passage>
      <infon key="volume">15</infon>
      <infon key="source">Nat Cell Biol</infon>
      <infon key="lpage">81</infon>
      <infon key="pub-id_pmid">23263282</infon>
      <infon key="fpage">72</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>51003</offset>
      <text>SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma</text>
    </passage>
    <passage>
      <infon key="volume">2</infon>
      <infon key="source">Ther Adv Hematol</infon>
      <infon key="lpage">379</infon>
      <infon key="pub-id_pmid">23556103</infon>
      <infon key="fpage">369</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>51144</offset>
      <text>The molecular biology of diffuse large B&#8208;cell lymphoma</text>
    </passage>
    <passage>
      <infon key="volume">11</infon>
      <infon key="source">Nat Rev Drug Discov</infon>
      <infon key="lpage">124</infon>
      <infon key="pub-id_pmid">22293567</infon>
      <infon key="fpage">109</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>51201</offset>
      <text>Targeting IAP proteins for therapeutic intervention in cancer</text>
    </passage>
    <passage>
      <infon key="volume">86</infon>
      <infon key="source">Cytometry B Clin Cytom</infon>
      <infon key="lpage">271</infon>
      <infon key="pub-id_pmid">24616127</infon>
      <infon key="fpage">263</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>51263</offset>
      <text>Clinical flow cytometric screening of SAP and XIAP expression accurately identifies patients with SH2D1A and XIAP/BIRC4 mutations</text>
    </passage>
    <passage>
      <infon key="volume">29</infon>
      <infon key="source">EMBO J</infon>
      <infon key="lpage">2420</infon>
      <infon key="pub-id_pmid">20526282</infon>
      <infon key="fpage">2407</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>51393</offset>
      <text>Phosphorylation of Mcl&#8208;1 by CDK1&#8208;cyclin B1 initiates its Cdc20&#8208;dependent destruction during mitotic arrest</text>
    </passage>
    <passage>
      <infon key="volume">21</infon>
      <infon key="source">Mol Cell Biol</infon>
      <infon key="lpage">3608</infon>
      <infon key="pub-id_pmid">11313486</infon>
      <infon key="fpage">3604</infon>
      <infon key="year">2001</infon>
      <infon key="type">ref</infon>
      <offset>51506</offset>
      <text>Characterization of XIAP&#8208;deficient mice</text>
    </passage>
    <passage>
      <infon key="volume">471</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">109</infon>
      <infon key="pub-id_pmid">21368833</infon>
      <infon key="fpage">104</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>51548</offset>
      <text>SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction</text>
    </passage>
    <passage>
      <infon key="volume">30</infon>
      <infon key="source">Oncogene</infon>
      <infon key="lpage">2809</infon>
      <infon key="pub-id_pmid">21339734</infon>
      <infon key="fpage">2799</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>51640</offset>
      <text>Mitosis as an anti&#8208;cancer target</text>
    </passage>
    <passage>
      <infon key="volume">70</infon>
      <infon key="source">Cancer Res</infon>
      <infon key="lpage">9276</infon>
      <infon key="pub-id_pmid">21045142</infon>
      <infon key="fpage">9265</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>51675</offset>
      <text>Deubiquitinase inhibition by small&#8208;molecule WP1130 triggers aggresome formation and tumor cell apoptosis</text>
    </passage>
    <passage>
      <infon key="volume">106</infon>
      <infon key="source">Proc Natl Acad Sci USA</infon>
      <infon key="lpage">14529</infon>
      <infon key="pub-id_pmid">19667203</infon>
      <infon key="fpage">14524</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>51782</offset>
      <text>XIAP mediates NOD signaling via interaction with RIP2</text>
    </passage>
    <passage>
      <infon key="volume">22</infon>
      <infon key="source">Curr Biol</infon>
      <infon key="lpage">R980</infon>
      <infon key="pub-id_pmid">23174302</infon>
      <infon key="fpage">R966</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>51836</offset>
      <text>The spindle assembly checkpoint</text>
    </passage>
    <passage>
      <infon key="volume">359</infon>
      <infon key="source">N Engl J Med</infon>
      <infon key="lpage">2323</infon>
      <infon key="pub-id_pmid">19038878</infon>
      <infon key="fpage">2313</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>51868</offset>
      <text>Stromal gene signatures in large&#8208;B&#8208;cell lymphomas</text>
    </passage>
    <passage>
      <infon key="volume">305</infon>
      <infon key="source">Science</infon>
      <infon key="lpage">1474</infon>
      <infon key="pub-id_pmid">15353805</infon>
      <infon key="fpage">1471</infon>
      <infon key="year">2004</infon>
      <infon key="type">ref</infon>
      <offset>51922</offset>
      <text>A small molecule Smac mimic potentiates TRAIL&#8208; and TNFalpha&#8208;mediated cell death</text>
    </passage>
    <passage>
      <infon key="volume">19</infon>
      <infon key="source">Cell Death Differ</infon>
      <infon key="lpage">377</infon>
      <infon key="pub-id_pmid">22223105</infon>
      <infon key="fpage">369</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>52006</offset>
      <text>Killing cells by targeting mitosis</text>
    </passage>
    <passage>
      <infon key="volume">132</infon>
      <infon key="source">Clin Immunol</infon>
      <infon key="lpage">123</infon>
      <infon key="pub-id_pmid">19398375</infon>
      <infon key="fpage">116</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>52041</offset>
      <text>Patients with X&#8208;linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T&#8208;cell populations</text>
    </passage>
    <passage>
      <infon key="volume">87</infon>
      <infon key="source">Crit Rev Oncol Hematol</infon>
      <infon key="lpage">171</infon>
      <infon key="pub-id_pmid">23375551</infon>
      <infon key="fpage">146</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>52174</offset>
      <text>Diffuse large B&#8208;cell lymphoma</text>
    </passage>
    <passage>
      <infon key="volume">122</infon>
      <infon key="source">Blood</infon>
      <infon key="lpage">1265</infon>
      <infon key="pub-id_pmid">23699601</infon>
      <infon key="fpage">1256</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>52206</offset>
      <text>Mutational and structural analysis of diffuse large B&#8208;cell lymphoma using whole&#8208;genome sequencing</text>
    </passage>
    <passage>
      <infon key="volume">15</infon>
      <infon key="source">Mol Biol Cell</infon>
      <infon key="lpage">1599</infon>
      <infon key="pub-id_pmid">14742711</infon>
      <infon key="fpage">1591</infon>
      <infon key="year">2004</infon>
      <infon key="type">ref</infon>
      <offset>52308</offset>
      <text>The FAM deubiquitylating enzyme localizes to multiple points of protein trafficking in epithelia, where it associates with E&#8208;cadherin and beta&#8208;catenin</text>
    </passage>
    <passage>
      <infon key="volume">12</infon>
      <infon key="source">Cell Death Differ</infon>
      <infon key="lpage">90</infon>
      <infon key="pub-id_pmid">15540113</infon>
      <infon key="fpage">87</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>52463</offset>
      <text>XIAP&#8208;deficiency leads to delayed lobuloalveolar development in the mammary gland</text>
    </passage>
    <passage>
      <infon key="volume">307</infon>
      <infon key="source">Science</infon>
      <infon key="lpage">1104</infon>
      <infon key="pub-id_pmid">15718471</infon>
      <infon key="fpage">1101</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>52546</offset>
      <text>Obligate role of anti&#8208;apoptotic MCL&#8208;1 in the survival of hematopoietic stem cells</text>
    </passage>
    <passage>
      <infon key="volume">20</infon>
      <infon key="source">Curr Opin Hematol</infon>
      <infon key="lpage">344</infon>
      <infon key="pub-id_pmid">23673341</infon>
      <infon key="fpage">336</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>52632</offset>
      <text>The genetic basis of diffuse large B&#8208;cell lymphoma</text>
    </passage>
    <passage>
      <infon key="volume">9</infon>
      <infon key="source">Lancet Oncol</infon>
      <infon key="lpage">116</infon>
      <infon key="pub-id_pmid">18226581</infon>
      <infon key="fpage">105</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>52685</offset>
      <text>Six versus eight cycles of bi&#8208;weekly CHOP&#8208;14 with or without rituximab in elderly patients with aggressive CD20+ B&#8208;cell lymphomas: a randomised controlled trial (RICOVER&#8208;60)</text>
    </passage>
    <passage>
      <infon key="volume">104</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">800</infon>
      <infon key="pub-id_pmid">11257232</infon>
      <infon key="fpage">791</infon>
      <infon key="year">2001</infon>
      <infon key="type">ref</infon>
      <offset>52867</offset>
      <text>Structural basis for the inhibition of caspase&#8208;3 by XIAP</text>
    </passage>
    <passage>
      <infon key="volume">444</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">114</infon>
      <infon key="pub-id_pmid">17080092</infon>
      <infon key="fpage">110</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>52926</offset>
      <text>XIAP deficiency in humans causes an X&#8208;linked lymphoproliferative syndrome</text>
    </passage>
    <passage>
      <infon key="volume">62</infon>
      <infon key="source">IUBMB Life</infon>
      <infon key="lpage">157</infon>
      <infon key="pub-id_pmid">20073038</infon>
      <infon key="fpage">140</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>53002</offset>
      <text>Emerging roles of deubiquitinases in cancer&#8208;associated pathways</text>
    </passage>
    <passage>
      <infon key="volume">463</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">107</infon>
      <infon key="pub-id_pmid">20023629</infon>
      <infon key="fpage">103</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>53068</offset>
      <text>Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival</text>
    </passage>
    <passage>
      <infon key="volume">30</infon>
      <infon key="source">Annu Rev Immunol</infon>
      <infon key="lpage">610</infon>
      <infon key="pub-id_pmid">22224767</infon>
      <infon key="fpage">565</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>53139</offset>
      <text>Pathogenesis of human B cell lymphomas</text>
    </passage>
    <passage>
      <infon key="volume">11</infon>
      <infon key="source">Mol Cell</infon>
      <infon key="lpage">527</infon>
      <infon key="pub-id_pmid">12620238</infon>
      <infon key="fpage">519</infon>
      <infon key="year">2003</infon>
      <infon key="type">ref</infon>
      <offset>53178</offset>
      <text>Mechanism of XIAP&#8208;mediated inhibition of caspase&#8208;9</text>
    </passage>
    <passage>
      <infon key="volume">4</infon>
      <infon key="source">Genes Cells</infon>
      <infon key="lpage">767</infon>
      <infon key="pub-id_pmid">10620020</infon>
      <infon key="fpage">757</infon>
      <infon key="year">1999</infon>
      <infon key="type">ref</infon>
      <offset>53233</offset>
      <text>The deubiquitinating enzyme Fam interacts with and stabilizes beta&#8208;catenin</text>
    </passage>
    <passage>
      <infon key="volume">131</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">681</infon>
      <infon key="pub-id_pmid">18022362</infon>
      <infon key="fpage">669</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>53310</offset>
      <text>IAP antagonists induce autoubiquitination of c&#8208;IAPs, NF&#8208;kappaB activation, and TNFalpha&#8208;dependent apoptosis</text>
    </passage>
    <passage>
      <infon key="volume">335</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">442</infon>
      <infon key="pub-id_pmid">3262202</infon>
      <infon key="fpage">440</infon>
      <infon key="year">1988</infon>
      <infon key="type">ref</infon>
      <offset>53424</offset>
      <text>Bcl&#8208;2 gene promotes haemopoietic cell survival and cooperates with c&#8208;myc to immortalize pre&#8208;B cells</text>
    </passage>
    <passage>
      <infon key="volume">6</infon>
      <infon key="source">Nat Rev Mol Cell Biol</infon>
      <infon key="lpage">297</infon>
      <infon key="pub-id_pmid">15803136</infon>
      <infon key="fpage">287</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>53530</offset>
      <text>IAPs, RINGs and ubiquitylation</text>
    </passage>
    <passage>
      <infon key="volume">131</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">693</infon>
      <infon key="pub-id_pmid">18022363</infon>
      <infon key="fpage">682</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>53561</offset>
      <text>IAP antagonists target cIAP1 to induce TNFalpha&#8208;dependent apoptosis</text>
    </passage>
    <passage>
      <infon key="volume">310</infon>
      <infon key="source">Science</infon>
      <infon key="lpage">1504</infon>
      <infon key="pub-id_pmid">16322459</infon>
      <infon key="fpage">1499</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>53631</offset>
      <text>Chromosome alignment and segregation regulated by ubiquitination of survivin</text>
    </passage>
    <passage>
      <infon key="volume">12</infon>
      <infon key="source">Nat Rev Mol Cell Biol</infon>
      <infon key="lpage">452</infon>
      <infon key="pub-id_pmid">21697901</infon>
      <infon key="fpage">439</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>53708</offset>
      <text>Ubiquitylation in apoptosis: a post&#8208;translational modification at the edge of life and death</text>
    </passage>
    <passage>
      <infon key="volume">111</infon>
      <infon key="source">Proc Natl Acad Sci USA</infon>
      <infon key="lpage">4256</infon>
      <infon key="pub-id_pmid">24591637</infon>
      <infon key="fpage">4251</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>53803</offset>
      <text>Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer</text>
    </passage>
    <passage>
      <infon key="volume">47</infon>
      <infon key="source">Semin Hematol</infon>
      <infon key="lpage">123</infon>
      <infon key="pub-id_pmid">20350658</infon>
      <infon key="fpage">115</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>53902</offset>
      <text>Rituximab: mechanism of action</text>
    </passage>
    <passage>
      <infon key="volume">471</infon>
      <infon key="source">Nature</infon>
      <infon key="lpage">114</infon>
      <infon key="pub-id_pmid">21368834</infon>
      <infon key="fpage">110</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>53933</offset>
      <text>Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7</text>
    </passage>
    <passage>
      <infon key="volume">2013</infon>
      <infon key="source">Hematology Am Soc Hematol Educ Program</infon>
      <infon key="lpage">590</infon>
      <infon key="pub-id_pmid">24319235</infon>
      <infon key="fpage">584</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>54008</offset>
      <text>Treatment strategies for aggressive lymphomas: what&#160;works?</text>
    </passage>
    <passage>
      <infon key="volume">28</infon>
      <infon key="source">J Clin Oncol</infon>
      <infon key="lpage">2380</infon>
      <infon key="pub-id_pmid">20385988</infon>
      <infon key="fpage">2373</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>54068</offset>
      <text>Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B&#8208;cell lymphoma in the rituximab era</text>
    </passage>
  </document>
</collection>
